InsiderClue
← All stocks

Edgewise Therapeutics, Inc.

EWTX Mostly scheduled
CIK 0001710072 #1406 in the set updated 18 Sep 2026
Bought (12 mo)
$199.40K
out of their own pocket, the only kind of buying there is
Sold (12 mo)
$19.50M
$506.73K on a plan · $18.71M straight out of an exercise
Sold at will
$290.37K
2 of 33 sales
Net
−$19.30M
−$90.96K against sales at will

By person

11 insiders · 34 transactions
Insider
Role
Bought
Sold
Net
Holding
Of company
Worth
Change
Russell Alan J
Chief Scientific Officer
—
$10.25M (6) scheduled
−$10.25M
31,466
0.0290%
$1.37M
+84.8%
Donovan Joanne M.
CMO
—
$4.62M (11) scheduled
−$4.62M
8,625
0.0079%
$374.38K
−66.6%
Edris Badreddin
Director
—
$3.40M (5) scheduled
−$3.40M
19,820
0.0182%
$860.32K
0.0%
KOCH KEVIN
President and CEO
—
$785.04K (3) scheduled
−$785.04K
52,488
0.0483%
$2.28M
+262.5%
Derakhshan Behrad
Chief Business Officer
—
$223.42K (4) scheduled
−$223.42K
31,826
0.0293%
$1.38M
+89.0%
MOORE JOHN R
General Counsel
—
$219.82K (4) scheduled
−$219.82K
17,697
0.0163%
$768.16K
+444.2%
Fox Jonathan C
Director
$199.40K (1)
—
+$199.40K
24,833
0.0229%
$1.08M
+128.7%
Thompson Peter A.
Director
—
—
—
443,792
0.4086%
$19.26M
—
ORBIMED ADVISORS LLC entity
Director
—
—
—
443,792
0.4086%
$19.26M
—
Carruthers R Michael
Chief Financial Officer
—
—
—
86,162
0.0793%
$3.74M
+133.3%
Semigran Marc
Chief Development Officer
—
—
—
6,716
0.0062%
$291.52K
0.0%

Individual transactions

29
Insider
Date
Role
Action
Shares
Price
Amount
KOCH KEVIN
12 Aug 2026
President and CEO
Sold after exercise
913
$44.33
$40.47K
KOCH KEVIN
12 Aug 2026
President and CEO
Sold after exercise
8,276
$43.66
$361.32K
KOCH KEVIN
12 Aug 2026
President and CEO
Sold after exercise
8,782
$43.64
$383.25K
Derakhshan Behrad
12 Aug 2026
Chief Business Officer
Sold after exercise
2,475
$43.70
$108.15K
Derakhshan Behrad
12 Aug 2026
Chief Business Officer
Sold after exercise
150
$44.44
$6.67K
Derakhshan Behrad
12 Aug 2026
Chief Business Officer
Sold after exercise
304
$44.50
$13.53K
Derakhshan Behrad
12 Aug 2026
Chief Business Officer
Sold after exercise
2,171
$43.79
$95.08K
MOORE JOHN R
12 Aug 2026
General Counsel
Sold after exercise
2,419
$43.80
$105.95K
MOORE JOHN R
12 Aug 2026
General Counsel
Sold after exercise
99
$44.50
$4.41K
MOORE JOHN R
12 Aug 2026
General Counsel
Sold after exercise
59
$44.41
$2.62K
MOORE JOHN R
12 Aug 2026
General Counsel
Sold after exercise
2,439
$43.81
$106.85K
Russell Alan J
12 Aug 2026
Chief Scientific Officer
Sold after exercise
390
$44.46
$17.34K
Russell Alan J
12 Aug 2026
Chief Scientific Officer
Sold after exercise
2,273
$43.68
$99.28K
Russell Alan J
12 Aug 2026
Chief Scientific Officer
Sold after exercise
3,238
$43.68
$141.43K
Donovan Joanne M.
12 Aug 2026
CMO
Sold after exercise
800
$44.52
$35.61K
Donovan Joanne M.
12 Aug 2026
CMO
Sold after exercise
104
$44.43
$4.62K
Donovan Joanne M.
12 Aug 2026
CMO
Sold after exercise
2,779
$43.71
$121.46K
Donovan Joanne M.
12 Aug 2026
CMO
Sold after exercise
2,839
$43.78
$124.30K
Russell Alan J
1 Jul 2026
Chief Scientific Officer
Sold after exercise
69,648
$39.41
$2.74M
Russell Alan J
1 Jul 2026
Chief Scientific Officer
Sold after exercise
130,352
$39.41
$5.14M
Donovan Joanne M.
5 May 2026
CMO
Sold after exercise
50,000
$38.57
$1.93M
Donovan Joanne M.
1 Apr 2026
CMO
Sold after exercise
28,662
$32.31
$926.10K
Donovan Joanne M.
31 Mar 2026
CMO
Sold after exercise
21,338
$32.12
$685.31K
Edris Badreddin
21 Jan 2026
Director
Sold after exercise
66,477
$29.44
$1.96M
Edris Badreddin
21 Jan 2026
Director
Sold after exercise
10,463
$29.44
$308.03K
Edris Badreddin
21 Jan 2026
Director
Sold after exercise
7,605
$29.44
$223.89K
Edris Badreddin
21 Jan 2026
Director
Sold after exercise
17,236
$29.44
$507.43K
Edris Badreddin
21 Jan 2026
Director
Sold after exercise
13,690
$29.44
$403.03K
Russell Alan J
12 Nov 2025
Chief Scientific Officer
Sold after exercise
100,000
$21.12
$2.11M
Show all 34 transactions →

What was left out

Form 4 filings counted 27
Amendments (4/A) skipped 5
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 2
Sales straight out of an exercise 29
Sales at will 2
Transactions with no price 0
Shares from compensation/vesting 608,578
History held since 30 Mar 2021